Reproducibility in Cancer Biology: What have we learned?

As the final outputs of the Reproducibility Project: Cancer Biology are published, it is clear that preclinical research in cancer biology is not as reproducible as it should be.
  1. Peter Rodgers  Is a corresponding author
  2. Andy Collings
  1. eLife, United Kingdom

Back in 2014, when the first articles from the Reproducibility Project: Cancer Biology (RPCB) were published in eLife, there were widespread concerns about what seemed to be low levels of replicability and reproducibility in some areas of research. Researchers at two drug companies – Bayer and Amgen – had reported that they had not been able to replicate many published findings in cancer biology and other areas of preclinical research (Prinz et al., 2011; Begley and Ellis, 2012). Since then large-scale studies of replicability and reproducibility in psychology, economics and other areas of research (Open Science Collaboration, 2015; Camerer et al., 2016), reports from learned societies (Academy of Medical Sciences, 2015; NAS, 2019), surveys of researchers (Baker, 2016; Boulbes et al., 2018), and popular books (Harris, 2017; Ritchie, 2020) have ensured that concerns about the 'reproducibility crisis' have maintained a high profile ever since.

The RPCB had two main aims: to provide evidence about replicability in preclinical cancer research, and to identify the factors that influence replicability more generally. Now, seven years later, the final three articles from the project have just been published, and they confirm that there is still considerable scope for improving the reproducibility of preclinical research in cancer biology (Errington et al., 2021a; Errington et al., 2021b; Errington et al., 2021c).

The RPCB was a collaboration between the Center for Open Science and Science Exchange, and the project was funded by a grant from a private foundation (now called Arnold Ventures). To achieve its aims the project team planned to repeat selected experiments from 53 high-profile papers in the field of cancer biology that had been published in the period 2010–2012. eLife agreed to be the publishing partner for the project, and to use what was then a new approach to peer review to assess the outputs of the project.

Under this approach, for each paper selected, the project team would prepare a Registered Report that described in detail how the experiments would be carried out and how the data would be analyzed. Each Registered Report would be peer reviewed, and experiments could not begin until it had been accepted for publication. The results of the experiments would then be written up as a Replication Study, which would be peer reviewed to ensure that the experiments and data analysis had been performed in accordance with the Registered Report. Where possible one of the authors of the original paper would be involved in the peer review of both the Registered Report and the Replication Study.

A total of 193 experiments from 53 papers were selected for replication, and the project team set about preparing Registered Reports for each paper. However, as recounted in detail in 'Challenges for assessing replicability in preclinical cancer biology' (Errington et al., 2021a), the team encountered problems almost immediately. For example, many of the original papers failed to report key descriptive and inferential statistics, and despite contacting the original authors the project team was unable to obtain these data for 68% of the experiments. Similarly, none of the 193 experiments were described in sufficient detail for the project team to design protocols to repeat them. And although the original authors were often helpful when asked for such details, they were 'not at all helpful' (or did not respond to the project team) for 32% of the experiments. These problems meant that the early stages of the project took longer than expected and went over budget: the end result was that it was only possible to publish 29 Registered Reports.

Once experimental work started, two-thirds of the protocols needed to be modified to allow the experiments to be completed. Again this stage of the project took longer and cost more than expected, and in the end the project team was only able to repeat 50 experiments from 23 papers: the results of these experiments are reported in 17 Replication Studies and an aggregate paper (Errington et al., 2021c). The clear message to emerge here is that the reporting of both methods and results needs to be improved.

So how replicable were the 50 experiments that the team managed to repeat? As explained in a meta-analysis that combines the data from all the replications (Errington et al., 2021b), there are a number of different answers to this question. One reason for this is that many of the experiments involved measuring more than one effect (such as measuring the influence of an intervention on both the tumor burden and overall survival). Indeed, the 50 experiments involved a total of 158 effects. Moreover, these effects could be positive effects or null effects. Furthermore, some of the original papers reported effects in terms of numerical values, whereas others relied on images.

The team used seven criteria to assess replicability, although some were not suitable for assessing all effects (e.g., some only worked for positive effects, or when numerical values were available). One criterion compared effect sizes for positive effects: this revealed the median effect size in the replications was 85% smaller than in the original experiments; moreover, the effect size in the replication was smaller than the original in 92% of cases. The other criteria were binary – the replication was either a success or a failure – and five of these could be used for both positive and null effects when effect sizes were reported as numerical values. For positive effects, 40% of replications succeeded according to three or more of these criteria, and this figure increased to 80% for null effects.

In a separate article, Patrick Kane and Jonathan Kimmelman (who were not part of the RPCB) take a step back and discuss some of the scientific, ethical and policy implications of the project (Kane and Kimmelman, 2021). They liken basic and preclinical research in cancer biology to a 'diagnostic machine' that is used to decide which clinical hypotheses should be progressed (including which should go forward to clinical trials). While the results of the RPCB may be 'concerning', Kane and Kimmelman argue that further work is needed to better understand the performance of the diagnostic machine.

And further work is being done on many fronts. National projects to explore various aspects of reproducibility are under way in several countries, including Brazil (Amaral et al., 2019; Amaral and Neves, 2021), Germany (BMBF, 2018) and the Netherlands (NWO, 2020). National reproducibility networks have also been set up in Germany and the UK.

The aim of the RPCB was not to find papers that were flawed or faulty, and a failure of the team to replicate an experiment does mean that the original was wrong (and, likewise, a successful replication does not guarantee that the original was correct – both the original and the replication may be wrong). However, the results of the project should give the biomedical research enterprise pause for thought. Journals have encouraged more complete reporting of methods and results in recent years, but there is still scope for improvement, especially when it comes to making data and code openly available. Many studies would benefit from greater input from experts in statistics, ideally before data are collected, and preregistration should help to reduce bias and increase rigor in certain types of studies. Increased preprinting will also help for most papers by increasing both readership and scrutiny, and by making new results available sooner. Lastly, a greater emphasis on science that is rigorous, as opposed to eye-catching, from researchers, institutions, funders and journals would benefit everyone.


All eLife content related to the Reproducibility Project: Cancer Biology is available at:

All underlying data, code, and digital materials for the project is available at:


  1. Book
    1. Harris R
    Rigor Mortis: How Sloppy Science Creates Worthless Cures, Crushes Hope, and Wastes Billions
    New York: Basic Books.
  2. Book
    1. Ritchie S
    Science Fictions: Exposing Fraud, Bias, Negligence and Hype in Science
    London: Bodley Head.

Article and author information

Author details

  1. Peter Rodgers

    Peter Rodgers is the Features Editor of eLife

    For correspondence
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8332-936X
  2. Andy Collings

    Andy Collings is the Executive Editor of eLife

    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9570-2061


The authors thank all the editors and reviewers who were involved in the peer review of RPCB articles.

Publication history

  1. Version of Record published: December 7, 2021 (version 1)
  2. Version of Record updated: December 17, 2021 (version 2)


© 2021, Rodgers and Collings

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.


  • 1,619
    Page views
  • 154
  • 0

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Peter Rodgers
  2. Andy Collings
Reproducibility in Cancer Biology: What have we learned?
eLife 10:e75830.

Further reading

    1. Cancer Biology
    2. Chromosomes and Gene Expression
    Justin H Hwang et al.
    Research Article Updated

    Metastatic castration-resistant prostate cancers (mCRPCs) are treated with therapies that antagonize the androgen receptor (AR). Nearly all patients develop resistance to AR-targeted therapies (ARTs). Our previous work identified CREB5 as an upregulated target gene in human mCRPC that promoted resistance to all clinically approved ART. The mechanisms by which CREB5 promotes progression of mCRPC or other cancers remains elusive. Integrating ChIP-seq and rapid immunoprecipitation and mass spectroscopy of endogenous proteins, we report that cells overexpressing CREB5 demonstrate extensive reprogramming of nuclear protein–protein interactions in response to the ART agent enzalutamide. Specifically, CREB5 physically interacts with AR, the pioneering actor FOXA1, and other known co-factors of AR and FOXA1 at transcription regulatory elements recently found to be active in mCRPC patients. We identified a subset of CREB5/FOXA1 co-interacting nuclear factors that have critical functions for AR transcription (GRHL2, HOXB13) while others (TBX3, NFIC) regulated cell viability and ART resistance and were amplified or overexpressed in mCRPC. Upon examining the nuclear protein interactions and the impact of CREB5 expression on the mCRPC patient transcriptome, we found that CREB5 was associated with Wnt signaling and epithelial to mesenchymal transitions, implicating these pathways in CREB5/FOXA1-mediated ART resistance. Overall, these observations define the molecular interactions among CREB5, FOXA1, and pathways that promote ART resistance.

    1. Cancer Biology
    2. Computational and Systems Biology
    Gökçe Senger et al.
    Research Article Updated

    Aneuploidy, a state of chromosome imbalance, is a hallmark of human tumors, but its role in cancer still remains to be fully elucidated. To understand the consequences of whole-chromosome-level aneuploidies on the proteome, we integrated aneuploidy, transcriptomic, and proteomic data from hundreds of The Cancer Genome Atlas/Clinical Proteomic Tumor Analysis Consortium tumor samples. We found a surprisingly large number of expression changes happened on other, non-aneuploid chromosomes. Moreover, we identified an association between those changes and co-complex members of proteins from aneuploid chromosomes. This co-abundance association is tightly regulated for aggregation-prone aneuploid proteins and those involved in a smaller number of complexes. On the other hand, we observed that complexes of the cellular core machinery are under functional selection to maintain their stoichiometric balance in aneuploid tumors. Ultimately, we provide evidence that those compensatory and functional maintenance mechanisms are established through post-translational control, and that the degree of success of a tumor to deal with aneuploidy-induced stoichiometric imbalance impacts the activation of cellular protein degradation programs and patient survival.